Track Bioglutide in Peptimes™
Bioglutide (research code NA-931) is an investigational drug from Biomed Industries, taken by mouth in its trials. Its Phase 2 registry record describes NA-931 as a peptide acting on four receptors: GLP-1, IGF-1, GIP and glucagon. (Source: ClinicalTrials.gov.)
Is Bioglutide FDA-approved?
No. Bioglutide (NA-931) is investigational: it's being studied in clinical trials and isn't FDA-approved for any use.
Bioglutide
Also: NA-931, NA931
- Status label in the Peptimes Library
- Phase 2 Trials
- Routes in Peptimes
- Oral
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-approved for any use. Drugs@FDA lists no application with Bioglutide (NA-931) as an active ingredient.
Source: Drugs@FDA, checked 1 Nov 2026
Investigational
Yes.
Source: ClinicalTrials.gov, checked 1 Nov 2026
How to track it in Peptimes
Add Bioglutide in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 2 Trials”, which describes its investigational status. It isn’t an approval.
- Logging: the amount you took and how you feel.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell Bioglutide or any other compound.
More sources
- NIH, ClinicalTrials.gov, NCT06564753, checked 1 Nov 2026: a completed Phase 2 study of NA-931 sponsored by Biomed Industries, and its description of NA-931.
- NIH, ClinicalTrials.gov, studies of NA-931, checked 1 Nov 2026: registered studies (Phase 1 and Phase 2).
- FDA, Drugs@FDA, searched 1 Nov 2026: no application lists Bioglutide or NA-931 as an active ingredient.